IBOGAINE RESEARCH & OPIOID ADDICTION

 Full article: Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes (tandfonline.com) (Overview presentation: Brown_GITA_Vancouver_Oct2012_iboga_comm_rev.pdf (maps.org))   

Thomas Kingsley Brown & Kenneth Alper

"Consistent with its apparent effect in opioid detoxification in humans, ibogaine administered intraperitoneally or intracerebrally to animals reduces naloxone- or naltrexone-precipitated opioid withdrawal signs, in rats, mice, and primates. Single dosages of ibogaine administered to rodents diminish self-administration of multiple abused substances including morphine , heron, cocaine, amphetamine, and alcohol, with normal responding for water. "

 Full article: Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study (tandfonline.com) (Overview Presentation: Microsoft PowerPoint - Cutting Edge Noller.ppt [Compatibility Mode] (maps.org

 "Conclusion: A single ibogaine treatment reduced opioid withdrawal symptoms and achieved opioid cessation or sustained reduced use in dependent individuals as measured over 12 months. Ibogaine’s legal availability in New Zealand may offer improved outcomes where legislation supports treatment providers to work closely with other health professionals."

  Geoffrey E. Noller, Chris M. Frampton & Berra Yazar-Klosinski

 (Both of the above studies are directly from the MAPS website, Ibogaine - Multidisciplinary Association for Psychedelic Studies - MAPS) 

Subjective effectiveness of ibogaine treatment for problematic opioid consumption: Short- and long-term outcomes and current psychological functioning - PMC (nih.gov)  Alan K. Davis, Joseph Barsuglia, Austin-Marley Windham Herman, Marta Lynch and Martin Polanco 

 "Results: Most participants (72%) had used opioids for at least 4 years and 69% reported daily use. Most (80%) indicated that ibogaine eliminated or drastically reduced withdrawal symptoms. Fifty percent reported that ibogaine reduced opioid craving, some (25%) reporting a reduction in craving lasting at least 3 months. Thirty percent of participants reported never using opioids again following ibogaine treatment. And over one half (54%) of these abstainers had been abstinent for at least 1 year, with 31% abstinent for at least 2 years. At the time of survey, 41% of all participants reported sustained abstinence (>6 months). Although 70% of the total sample reported a relapse following treatment, 48% reported decreased use from pretreatment levels and an additional 11% eventually achieved abstinence. Treatment responders had the lowest rates of depressive and anxious symptoms, the highest levels of subjective well-being and rated their ibogaine treatment as more spiritually meaningful compared with treatment non-responders. "

"Conclusion:  The results suggest that ibogaine is associated with reductions in opioid use, including complete abstinence, and has long-term positive psychological outcomes. Future research should investigate the efficacy of ibogaine treatment using rigorous longitudinal and controlled designs. "

Ibogaine Detoxification Transitions Opioid and Cocaine Abusers Between Dependence and Abstinence: Clinical Observations and Treatment Outcomes - PMC (nih.gov)   

Deborah C. Mash, Linda Duque, Bryan Page, and Kathleen Allen-Ferdinand

" High rates of depressive disorders are reported among people seeking treatment for substance abuse disorders (for review, Nunes and Levin, 2004). The rapid improvement in depressive mood following ibogaine administration may offer an additional benefit for opioid detoxification when compared to an opioid substitution taper or lofexidine as withdrawal agents... Ibogaine may help opioid dependent patients to transition to sobriety and to establish a substance-free recovery because the oneirophrenic effects have therapeutic benefit as an adjuvant to psychotherapy (Alper et al., 1999; Davis et al., 2017; Mash, 2018). The elicitation narratives described in this report suggest that ibogaine may promote harm reduction following detoxification from opioids. "

 The efficacy of ibogaine use in opioid use disorder compared to buprenorphine  PowerPoint Presentation (ucdavis.edu)   

(SEE POWERPOINT SLIDE BELOW)